文献速递胃肠外科围术期管理与 ERAS

全球腹膜后肉瘤诊疗模式差异:RESAR登记处分析

Global Variations in Patterns of Care for Retroperitoneal Sarcoma.
PubMed 文献 · Ann Surg · 2025-06-16

基于19个转诊中心RESAR前瞻登记(2017-2022)的1718例原发腹膜后肉瘤回顾分析,评估诊断、手术及(新)辅助治疗的模式差异。非脂肪肉瘤术前活检、脂肪肉瘤化疗和平滑肌肉瘤放疗使用率变异小,提示中心间一致;脂肪肉瘤完整切除和平滑肌肉瘤化疗变异大,提示临床均势。STRASS试验发表后放疗使用显著下降(19%→14%,P=0.045)。

要点

  • 非脂肪肉瘤术前活检使用率高(中位98%),中心间变异小。
  • 脂肪肉瘤完整切除率中位64%,低容量中心变异大于高容量中心。
  • STRASS试验发表后放疗使用显著下降(19%→14%,P=0.045)。

核心结论

  • 非脂肪肉瘤术前活检、脂肪肉瘤化疗和平滑肌肉瘤放疗的使用在各中心间变异小,提示存在共识。
  • 脂肪肉瘤完整切除的价值和平滑肌肉瘤化疗的作用存在高度变异,提示临床均势。
  • STRASS试验结果似乎已被接受,发表后放疗使用减少。

研究设计与样本

  • 回顾性分析RESAR前瞻性登记(NCT03838718)中2017年2月至2022年7月收治的原发腹膜后肉瘤。
  • 纳入全球19个腹膜后肉瘤转诊中心,共1718例原发腹膜后肉瘤。
  • 中心按容量分为高容量中心(HVC)和低容量中心(LVC)。
  • 完整切除(CR)定义为整块切除同侧肾脏和结肠。

主要发现

  • 实体(非脂肪肉瘤)腹膜后肉瘤术前活检使用频繁,中位率98%。
  • 脂肪肉瘤中完整切除的中位率为64%,变异大(IQR 37% [43%-80%],范围0-100%)。
  • 脂肪肉瘤完整切除在LVC的变异(IQR 39.5% [40.5%-80%])大于HVC(IQR 9.5% [58.3%-67.8%])。
  • 围手术期化疗在脂肪肉瘤中很少使用(中位0%),在平滑肌肉瘤中中位率为10%但变异大(IQR 26% [2%-28%])。
  • 放疗在平滑肌肉瘤中一直使用较少(IQR 13% [0%-13%]),HVC使用率高于LVC(中位HVC 18.5% vs. LVC 5%)。

临床怎么用

  • 非脂肪肉瘤术前应常规活检,各中心对此已有高度共识。
  • 脂肪肉瘤完整切除的适应证仍存争议,需个体化决策并参考高容量中心经验。
  • 平滑肌肉瘤围手术期化疗的作用存在均势,应鼓励患者纳入临床试验。
  • STRASS试验结果已影响实践,平滑肌肉瘤放疗使用应更趋谨慎。

局限性

  • 回顾性分析登记数据,可能存在选择偏倚和信息偏倚。
  • 中心分类仅基于容量,未详细说明容量阈值定义。
  • 未报告各中心的具体治疗方案细节和长期肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine variations in patterns of care for retroperitoneal sarcoma (RPS) among sarcoma centres globally, including diagnostic work-up, surgical strategies and (neo)adjuvant therapies. METHODS: Retrospective analysis for primary RPS, from 19 RPS referral centres worldwide, prospectively collected within the RESAR repository (NCT03838718) between Feb 2017 - July 2022. Centres were categorised high volume (HVC) or low volume (LVC). Comprehensive resection (CR) was defined as en-bloc resection of ipsilateral kidney and colon. RESULTS: 1718 primary RPS were included. Preoperative biopsy was utilised frequently (median rate 98%) for solid (non-liposarcoma) RPS. In liposarcoma, the median rate of CR was 64%, with wide variation (IQR 37% [43%-80%], range 0-100%). There was greater variation in CR in liposarcoma in LVC (IQR 39.5% [40.5%-80%]) versus HVC (IQR 9.5% [58.3%-67.8%]). Perioperative chemotherapy was seldom used for liposarcoma (median 0%), with higher rates for leiomyosarcoma (median 10%) with high variation (IQR 26% [2%-28%]). Radiotherapy was used consistently infrequently in leiomyosarcoma (IQR 13% [0%-13%]. There was higher use of radiotherapy in HVC than LVC (median HVC 18.5% vs. LVC 5%). There was a significant decrease in radiotherapy use after the STRASS trial (pre 19% vs. post 14%, P=0.045). CONCLUSIONS: Low variation was found in pre-operative biopsy of non-liposarcomas, use of chemotherapy in liposarcoma and radiotherapy in leiomyosarcoma, suggesting agreement between centres. There was high variation, suggesting equipoise, in the role of chemotherapy in leiomyosarcoma and the value of CR in liposarcoma. The STRASS study results seem to have been accepted, with a reduction in radiotherapy after its publication.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Snow H, Fiore M, Xie J, et al. Global Variations in Patterns of Care for Retroperitoneal Sarcoma. Ann Surg. 2025. PMID: 40519020. doi:10.1097/SLA.0000000000006791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。